CSL (OTCMKTS:CSLLY) Hits New 12-Month Low Following Analyst Downgrade

Key Points

• CSL Limited's share price reached a new 52-week low at $64.68, closing later at $66.98 with a trading volume of only 1,054 shares.
• The company has a current ratio of 2.46, indicating strong liquidity, and a low debt-to-equity ratio of 0.50, suggesting relatively low leverage.
• CSL operates through several segments, including CSL Behring, which specializes in plasma products and gene therapies, reflecting the company's focus on biopharmaceuticals and vaccines.

CSL Limited Sponsored ADR (OTCMKTS:CSLLY - Get Free Report) hit a new 52-week low on Tuesday after Zacks Research downgraded the stock from a hold rating to a strong sell rating. The stock traded as low as $64.68 and last traded at $66.98, with a volume of 1054 shares changing hands. The stock had previously closed at $67.61.

CSL Stock Down 0.7%

The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12. The business's fifty day moving average is $77.79 and its two-hundred day moving average is $78.37.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.